Ground Swell Capital’s PharmaCyte Biotech PMCB Stock Holding History

Ground Swell Capital’s Portfolio PMCB Stock Details PMCB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-11,527	Closed	-$7.67K	–	203
2026 Q1	$7.67K	Buy	+11,527	New	+$8.82K	0.02%	104

Other funds holding PMCB

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Ground Swell Capital's PMCB Position: Q2 2026 in Review

Ground Swell Capital sold out of PharmaCyte Biotech (PMCB) in Q2 2026, closing a stake of 11,527 shares — an estimated $7.67K sold.

Ground Swell Capital first reported a position in PMCB in Q1 2026 and held it in 1 quarter. The position peaked at $7.67K in Q1 2026. 28 funds tracked by Wall St. Rank hold PMCB as of Q2 2026.

Ground Swell Capital reported no remaining PharmaCyte Biotech position as of Q2 2026 after selling out during the quarter.
Ground Swell Capital sold 11,527 PharmaCyte Biotech shares in Q2 2026, an estimated $7.67K.
Ground Swell Capital first reported a position in PharmaCyte Biotech in Q1 2026 and held it in 1 quarter.
Ground Swell Capital's PharmaCyte Biotech position peaked at $7.67K in Q1 2026.
28 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q2 2026.

Based on Ground Swell Capital's 13F filing for Q2 2026, filed 5 Aug 2026.